Orchestra BioMed Holdings Capital Raise of $86.3M
Orchestra BioMed closed an underwritten public offering of 17,250,000 shares of common stock, which included the full exercise of the underwriters' over-allotment option. The offering was priced at $5.00 per share, generating gross proceeds of approximately $86.3 million. The company intends to use the funds to support its AVIM Therapy and Virtue SAB clinical programs, including the BACKBEAT global pivotal trial.
- Value
- $86.3M
- Counterparty
- Piper Sandler & Co.